0000000000798613
AUTHOR
Waqar Hassan
SNOMED on FHIR Transmission of clinical data with the Fast Healthcare Interoperability Resources protocol (HL7-FHIR) utilizing Systematized Nomenclature of Medicine - Clinical Terms (SNOMED-CT)
Master's thesis Information- and communication technology IKT590 - University of Agder 2019 The exchange of information at the level of semantic interoperability needs some infor-mation model and clinical terminology work together. Electronic records of the patientmust include the terminologies in order to give the decision support to the practitionerwhen needed. Due to the lack of common standards for data structure and data sharingcreates the problem to interact and share information with different applications.Our main goal in this thesis is transferring the SNOMED-CT (Systematized Nomenclatureof Medicine Clinical Terms) terminologies using HL7 FHIR (Fast Healthcare Interoper-ability Res…
Regional and experiential differences in surgeon preference for the treatment of cervical facet injuries: a case study survey with the AO Spine Cervical Classification Validation Group
Abstract Purpose The management of cervical facet dislocation injuries remains controversial. The main purpose of this investigation was to identify whether a surgeon’s geographic location or years in practice influences their preferred management of traumatic cervical facet dislocation injuries. Methods A survey was sent to 272 AO Spine members across all geographic regions and with a variety of practice experience. The survey included clinical case scenarios of cervical facet dislocation injuries and asked responders to select preferences among various diagnostic and management options. Results A total of 189 complete responses were received. Over 50% of responding surgeons in each region…
Pharmacogenetics of treatments for pancreatic cancer
Introduction: Despite clinical efforts, pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The scarcity of effective therapies can be reflected by the lack of reliable biomarkers to adapt anticancer drugs prescription to tumors’ and patients’ features. Areas covered: Pharmacogenetics should provide the way to select patients who may benefit from a specific therapy that best matches individual and tumor genetic profile, but it has not yet led to gains in outcome. This review describes PDAC pharmacogenetics findings, critically reappraising studies on polymorphisms and -omics profiles correlated to response to gemcitabine, FOLFIRINOX, and nab-paclitaxel combinations, as well as l…